InspireMD (NYSE:NSPR – Get Rating) and Longview Acquisition Corp. II (NYSE:LGV – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and target prices for InspireMD and Longview Acquisition Corp. II, as provided by MarketBeat.
Get InspireMD alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InspireMD | 0 | 0 | 0 | 0 | N/A |
| Longview Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares InspireMD and Longview Acquisition Corp. II's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InspireMD | -321.14% | -64.03% | -52.30% |
| Longview Acquisition Corp. II | N/A | -65.52% | 3.65% |
Institutional & Insider Ownership
1.3% of InspireMD shares are owned by institutional investors. Comparatively, 66.3% of Longview Acquisition Corp. II shares are owned by institutional investors. 3.8% of InspireMD shares are owned by insiders. Comparatively, 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
InspireMD has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Longview Acquisition Corp. II has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Valuation & Earnings
This table compares InspireMD and Longview Acquisition Corp. II's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InspireMD | $4.49 million | 2.41 | -$14.92 million | ($2.27) | -0.57 |
| Longview Acquisition Corp. II | N/A | N/A | $7.40 million | N/A | N/A |
Longview Acquisition Corp. II has lower revenue, but higher earnings than InspireMD.
Summary
Longview Acquisition Corp. II beats InspireMD on 5 of the 8 factors compared between the two stocks.
About InspireMD
(Get Rating)
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.
About Longview Acquisition Corp. II
(Get Rating)
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.